MX343604B - Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. - Google Patents
Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.Info
- Publication number
- MX343604B MX343604B MX2012013579A MX2012013579A MX343604B MX 343604 B MX343604 B MX 343604B MX 2012013579 A MX2012013579 A MX 2012013579A MX 2012013579 A MX2012013579 A MX 2012013579A MX 343604 B MX343604 B MX 343604B
- Authority
- MX
- Mexico
- Prior art keywords
- ldh
- pdhk
- downregulating
- polypeptide production
- increasing polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
- C12Y102/04001—Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a métodos y composiciones para reducir producción de lactato e incrementar producción de polipéptido en células cultivadas. En un aspecto, la invención proporciona un método que comprende cultivar células que expresan a) un RNA pequeño interferente (siRNA) específico para una lactato dehidrogenasa (LDH) y b) un siRNA específico para una piruvato dehidrogenasa quinasa (PDHK). En otro aspecto, la invención proporciona células cultivadas o vectores que comprenden un siRNA específico para un LDH y un siRNA específico para un PDHK.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34972710P | 2010-05-28 | 2010-05-28 | |
PCT/US2011/038191 WO2011150241A2 (en) | 2010-05-28 | 2011-05-26 | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012013579A MX2012013579A (es) | 2013-01-24 |
MX343604B true MX343604B (es) | 2016-11-11 |
Family
ID=45004831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013579A MX343604B (es) | 2010-05-28 | 2011-05-26 | Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. |
MX2020009460A MX2020009460A (es) | 2010-05-28 | 2012-11-22 | Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020009460A MX2020009460A (es) | 2010-05-28 | 2012-11-22 | Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. |
Country Status (15)
Country | Link |
---|---|
US (4) | US9487809B2 (es) |
EP (1) | EP2576580B1 (es) |
JP (3) | JP6050226B2 (es) |
KR (3) | KR101989762B1 (es) |
CN (1) | CN102985437B (es) |
BR (1) | BR112012030197A2 (es) |
CA (1) | CA2800728C (es) |
DK (1) | DK2576580T3 (es) |
ES (1) | ES2599412T3 (es) |
HU (1) | HUE030820T2 (es) |
MX (2) | MX343604B (es) |
PL (1) | PL2576580T3 (es) |
RU (1) | RU2614125C2 (es) |
SI (1) | SI2576580T1 (es) |
WO (1) | WO2011150241A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
TW201516149A (zh) | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
RU2520838C2 (ru) | 2008-10-20 | 2014-06-27 | Эббви Инк | Выделение и очистка антител с использованием аффинной хроматографии на основе белка а |
CN104974251A (zh) | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
CA2800728C (en) | 2010-05-28 | 2020-10-27 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
SI3019619T1 (sl) | 2013-07-11 | 2021-12-31 | Modernatx, Inc. | Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
EP3812453A1 (en) * | 2013-10-11 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015142903A2 (en) * | 2014-03-17 | 2015-09-24 | Genentech, Inc. | Method of controlling lactate production with piperdine-dione derivatives |
JP6688292B2 (ja) * | 2014-10-10 | 2020-04-28 | ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. | 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害 |
KR102265924B1 (ko) * | 2014-10-31 | 2021-06-15 | 삼성바이오에피스 주식회사 | Pdk 불활성화에 의한 폴리펩타이드의 생산 |
WO2016125937A1 (ko) * | 2015-02-06 | 2016-08-11 | 경북대학교 산학협력단 | Pdk2를 이용한 여성 갱년기 질환 예방 또는 치료제의 스크리닝 방법 및 상기 방법으로 스크리닝 된 치료제를 유효성분으로 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학적 조성물 |
CN105368839A (zh) * | 2015-12-22 | 2016-03-02 | 中国人民解放军第三军医大学 | 一种有效抑制小鼠pdk2表达的rna干扰序列及其应用 |
WO2017192437A1 (en) * | 2016-05-02 | 2017-11-09 | The Regents Of The University Of California | Mammalian cells devoid of lactate dehydrogenase activity |
EP4265261A3 (en) | 2017-10-13 | 2024-01-24 | Novo Nordisk Health Care AG | Methods and compositions for inhibiting expression of ldha |
CN107904257B (zh) * | 2017-11-22 | 2021-05-04 | 上海药明生物技术有限公司 | 一种增加cho细胞群蛋白表达量的方法 |
US11661586B2 (en) | 2017-12-04 | 2023-05-30 | The General Hospital Corporation | Extracellular redox enzyme system to alleviate disease |
AU2019245243A1 (en) * | 2018-03-29 | 2020-09-03 | Genentech, Inc | Modulating lactogenic activity in mammalian cells |
MX2021015823A (es) * | 2019-06-26 | 2022-02-03 | Hoffmann La Roche | Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1). |
CN115948404B (zh) * | 2023-02-01 | 2024-06-04 | 重庆医科大学 | 一种抑制环状RNA circPDHK1的siRNA及其用途 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
ATE113846T1 (de) | 1988-06-21 | 1994-11-15 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2113813C (en) | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
ZA936128B (en) | 1992-08-21 | 1995-02-20 | Genentech Inc | Method for treating a LFA-1 mediated disorder |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CA2176811C (en) | 1993-12-10 | 2008-01-29 | David Tai Wai Fei | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
ATE164079T1 (de) | 1994-01-18 | 1998-04-15 | Genentech Inc | Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten |
US5707622A (en) | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
DE69714966T2 (de) | 1996-01-23 | 2003-04-24 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
US5726856A (en) | 1996-02-28 | 1998-03-10 | General Electric Company | Hexasubstituted guanidinium salts and ultracapacitors employing them as electrolytes |
US5714388A (en) | 1996-08-14 | 1998-02-03 | Bayer Corporation | Apparatus and method for detecting chemiluminescent light |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
KR100532178B1 (ko) | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-CD11a 항체 |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
DK1860187T3 (da) | 1997-05-15 | 2011-10-31 | Genentech Inc | Apo-2-receptor |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
CA2376228A1 (en) | 1999-06-17 | 2000-12-28 | Martha K. Newell | Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells |
KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
NZ518477A (en) | 1999-10-29 | 2004-10-29 | Genentech Inc | Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo |
AU2001275897A1 (en) * | 2000-07-12 | 2002-01-21 | Immunex Corporation | Improvement of cell culture performance |
IL159756A0 (en) * | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
WO2006085942A2 (en) | 2004-06-17 | 2006-08-17 | The Regents Of The University Of California | Compositions and methods for regulating gene transcription |
US20090209618A1 (en) * | 2004-10-08 | 2009-08-20 | Dang Chi V | Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases |
RU2487168C2 (ru) | 2007-08-07 | 2013-07-10 | Чугаи Сейяку Кабусики Кайся | Способ получения гетерологичных белков |
US20090325287A1 (en) * | 2008-06-13 | 2009-12-31 | Haimanti Dorai | Methods for Obtaining High Viable Cell Density in Mammalian Cell Culture |
PL2326720T3 (pl) * | 2008-09-15 | 2018-08-31 | F. Hoffmann-La Roche Ag | Kompozycje i sposoby regulacji osmolarności komórki |
CA2800728C (en) | 2010-05-28 | 2020-10-27 | Genentech, Inc. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2011
- 2011-05-26 CA CA2800728A patent/CA2800728C/en active Active
- 2011-05-26 PL PL11787435T patent/PL2576580T3/pl unknown
- 2011-05-26 ES ES11787435.4T patent/ES2599412T3/es active Active
- 2011-05-26 KR KR1020187016873A patent/KR101989762B1/ko active IP Right Grant
- 2011-05-26 HU HUE11787435A patent/HUE030820T2/en unknown
- 2011-05-26 EP EP11787435.4A patent/EP2576580B1/en active Active
- 2011-05-26 JP JP2013512251A patent/JP6050226B2/ja active Active
- 2011-05-26 DK DK11787435.4T patent/DK2576580T3/en active
- 2011-05-26 MX MX2012013579A patent/MX343604B/es active IP Right Grant
- 2011-05-26 WO PCT/US2011/038191 patent/WO2011150241A2/en active Application Filing
- 2011-05-26 BR BR112012030197A patent/BR112012030197A2/pt not_active Application Discontinuation
- 2011-05-26 CN CN201180026517.2A patent/CN102985437B/zh active Active
- 2011-05-26 KR KR1020197016381A patent/KR20190067277A/ko not_active Application Discontinuation
- 2011-05-26 RU RU2012157307A patent/RU2614125C2/ru active
- 2011-05-26 KR KR1020127033948A patent/KR101869987B1/ko not_active Application Discontinuation
- 2011-05-26 SI SI201131017A patent/SI2576580T1/sl unknown
-
2012
- 2012-11-22 MX MX2020009460A patent/MX2020009460A/es unknown
- 2012-11-28 US US13/688,075 patent/US9487809B2/en active Active
-
2016
- 2016-09-16 US US15/268,424 patent/US10011856B2/en active Active
- 2016-11-24 JP JP2016227876A patent/JP6325060B2/ja active Active
-
2018
- 2018-04-11 JP JP2018076234A patent/JP6706642B2/ja active Active
- 2018-05-31 US US15/994,950 patent/US10704071B2/en active Active
-
2020
- 2020-05-29 US US16/888,344 patent/US11046987B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343604B (es) | Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. | |
MY193665A (en) | Recombinant microorganisms and uses therefor | |
MY158160A (en) | Improved isoprene production using the dxp and mva pathway | |
GB2513732A (en) | Methods and compositions for sample identification | |
MY156588A (en) | Systems using cell culture for production of isoprene | |
WO2010048417A3 (en) | Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products | |
EP2633036A4 (en) | METHODS OF DIFFERENTIATION FOR THE PRODUCTION OF GLIAL CELL POPULATIONS | |
EP4379578A3 (en) | Learning situations via pattern matching | |
MY195387A (en) | Microorganisms for the Production of 1,4-Butanediol and Related Methods | |
WO2010096588A3 (en) | Cell culture media containing combinations of proteins | |
MX355504B (es) | Éster de cera de proteína portadora de acil-acil sintasas. | |
WO2012058494A3 (en) | Isoprene synthase variants for improved production of isoprene | |
SG10201810830UA (en) | Cell culture compositions and methods for polypeptide production | |
WO2010059902A3 (en) | 3d cell-culture article and methods thereof | |
NZ600585A (en) | Expression of hexose kinase in recombinant host cells | |
MY178338A (en) | Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants | |
MX2011006301A (es) | Produccion de alcoholes de cadena ramificada por medio de microorganismos fotosinteticos. | |
WO2012102527A3 (ko) | 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도 | |
WO2012003402A3 (en) | Compositions and methods for culturing microorganisms | |
MY182946A (en) | Production of organic acids by fermentation at low ph | |
WO2012177983A3 (en) | Microorganisms for producing ethylene glycol and methods related thereto | |
MX2013006105A (es) | Metodo de operacion de la fermentacion de un substrato gaseoso que comprende hidrogeno. | |
WO2011109612A3 (en) | Method for selecting an ips cell | |
WO2013096683A3 (en) | Enhanced production of isoprene using marine bacterial cells | |
WO2012016172A3 (en) | Genetically modified microbes producing increased levels of acetyl-coa derived compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |